Navigating Uncharted Waters: Steering the Course and Confronting Challenges of Brain Metastases in EGFR-Mutant Lung Cancer
Authors:
- Daniela GarcezDGDaniela Garcez
- Ana RodriguesAna Rodrigues
- Catarina TravancinhaCTCatarina Travancinha
- Marcos PantarottoMPMarcos Pantarotto
- Paulo CostaPCPaulo Costa
- António AraújoAAAntónio Araújo
- Juan RachadellJuan Rachadell
- João Ramalho-CarvalhoJRJoão Ramalho-Carvalho
- Ana FigueiredoAFAna Figueiredo
- Telma SequeiraTSTelma Sequeira
- Maria Gabriela O. FernandesMFMaria Gabriela O. Fernandes
Preprint
- 8 July 2026
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Brain metastases represent a major clinical challenge in the management of non-small cell lung cancer, particularly in patients with epidermal growth factor receptor mutations constituting a leading cause of morbidity and mortality. In recent years, significant advancements have been made in both local therapies and systemic treatments. Nevertheless, managing central nervous system disease remains complex, encompassing challenges such as optimal therapy sequencing, resistance mechanisms, oligoprogression, the role of the blood-brain barrier, diagnostic strategies, and the influence of the brain tumor microenvironment. Despite advances, brain metastases in non-small cell lung cancer remain an unmet need. Local treatments like radiotherapy are effective but carry risks of long-term neurological side effects, while the number and burden of brain metastases remain key prognostic factors. Surgical resection may be considered even in patients with multiple brain metastases to improve clinical status, enable further therapy, and enhance survival and quality of life. With the extension of survival afforded by systemic therapies, optimizing the balance between treatment efficacy and quality of life has become critical. Integrating patient perspectives is essential in navigating these complex clinical decisions.Keywords
All Related Versions
- Version 1, 2026-07-08, Preprints
- Published version: Cancers, 18 (16), 2647.
This publication has 137 references indexed in Scilit:
- Prognosticators of osimertinib treatment outcomes in patients with EGFR-mutant non-small cell lung cancer and leptomeningeal metastasisJournal of Cancer Research and Clinical Oncology, 2022
- Sequencing of cerebrospinal fluid in non‐small‐cell lung cancer patients with leptomeningeal metastasis: A systematic reviewCancer Medicine, 2022
- Systemic Therapy for Lung Cancer Brain MetastasesCurrent Treatment Options in Oncology, 2021
- Extracellular vesicles in the development of organ‐specific metastasisJournal of Extracellular Vesicles, 2021
- Bevacizumab suppresses the growth of established non-small-cell lung cancer brain metastases in a hematogenous brain metastasis modelClinical & Experimental Metastasis, 2019
- High probability and frequency of EGFR mutations in non-small cell lung cancer with brain metastasesJournal of Neuro-Oncology, 2017
- Novel Treatment Strategies for Brain Metastases in Non-small-cell Lung CancerCurrent Treatment Options in Oncology, 2016
- Treatment of Malignant Brain Tumor by Tumor‐Triggered Programmed Wormlike Micelles with Precise Targeting and Deep PenetrationAdvanced Functional Materials, 2016
- E-cadherin as a predictive marker of brain metastasis in non-small-cell lung cancer, and its regulation by pioglitazone in a preclinical modelJournal of Neuro-Oncology, 2012
- Matrix metalloproteinases stimulate epithelial-mesenchymal transition during tumor developmentClinical & Experimental Metastasis, 2008